STOCK TITAN

[Form 4/A] CorMedix Inc. Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

CorMedix insider amendment reports a tax-withholding share disposition by Elizabeth Hurlburt, the company's Chief Operating Officer and a director. The filing shows 8,424 shares of common stock were withheld by the issuer at an effective price of $14.83 to satisfy the reporting person's tax liability, reducing her direct beneficial ownership to 176,990 shares. The Form 4/A amends an earlier filing to disclose this withheld amount. The disclosure is a mechanical equity withholding for taxes rather than an open-market sale and does not report derivative transactions.

Una modifica interna di CorMedix segnala una cessione di azioni per ritenuta fiscale effettuata da Elizabeth Hurlburt, Chief Operating Officer e membro del consiglio. La comunicazione indica che 8.424 azioni ordinarie sono state trattenute dall'emittente a un prezzo effettivo di 14,83$ per coprire l'obbligo fiscale della soggetta alla segnalazione, riducendo la sua partecipazione diretta a 176.990 azioni. Il Modulo 4/A corregge una dichiarazione precedente per includere questa ritenuta. Si precisa che si tratta di una trattenuta automatica per tasse e non di una vendita sul mercato aperto, e che non sono state riportate operazioni su strumenti derivati.

Una enmienda interna de CorMedix informa de una disposición de acciones retenidas por impuestos realizada por Elizabeth Hurlburt, la directora de operaciones y miembro del consejo. El documento muestra que 8.424 acciones ordinarias fueron retenidas por el emisor a un precio efectivo de 14,83$ para satisfacer la obligación fiscal de la persona informante, reduciendo su propiedad beneficiaria directa a 176.990 acciones. El Formulario 4/A enmienda una presentación previa para revelar este importe retenido. Se aclara que se trata de una retención de acciones por impuestos de carácter mecánico, no de una venta en el mercado abierto, y no se informan transacciones con derivados.

코르메딕스 내부 수정 보고서에 따르면 최고운영책임자(COO) 겸 이사인 엘리자베스 헐버트가 세금 원천징수를 위해 주식을 처분한 것으로 보고되었습니다. 제출서류에는 보고자의 세금 부담을 충당하기 위해 발행사가 보통주 8,424주를 유효 가격 주당 14.83달러로 원천징수했으며, 이에 따라 그녀의 직접적 실질 소유는 176,990주로 감소했다고 기재되어 있습니다. Form 4/A는 이전 제출을 정정하여 이 원천징수분을 공개합니다. 이는 개방 시장에서의 매도가 아니라 세금을 위한 기계적 주식 원천징수이며, 파생상품 거래는 보고되지 않았습니다.

Un amendement interne de CorMedix signale une cession d'actions par retenue fiscale réalisée par Elizabeth Hurlburt, directrice des opérations et administratrice. Le dépôt indique que 8 424 actions ordinaires ont été retenues par l'émetteur à un prix effectif de 14,83 $ afin de couvrir la responsabilité fiscale de la personne déclarante, réduisant ainsi sa participation directe à 176 990 actions. Le formulaire 4/A corrige une déclaration antérieure pour divulguer ce montant retenu. Il s'agit d'une retenue d'actions à des fins fiscales de nature mécanique, et non d'une vente sur le marché ouvert, et aucune transaction sur dérivés n'est déclarée.

Eine interne Änderung bei CorMedix meldet eine aktienbezogene Steuerabzugsverfügung durch Elizabeth Hurlburt, die Chief Operating Officer und Direktorin des Unternehmens. Die Einreichung zeigt, dass 8.424 Stammaktien vom Emittenten zu einem effektiven Preis von 14,83$ einbehalten wurden, um die Steuerpflicht der meldepflichtigen Person zu erfüllen, wodurch ihr direktes wirtschaftliches Eigentum auf 176.990 Aktien reduziert wurde. Das Formular 4/A ändert eine frühere Meldung, um diesen einbehaltenen Betrag offenzulegen. Es handelt sich um eine mechanische Steuerabzugsmaßnahme und nicht um einen Verkauf am offenen Markt; Derivatgeschäfte wurden nicht gemeldet.

Positive
  • Amendment improves disclosure by reporting previously omitted tax-withholding shares, increasing transparency
  • Transaction is a tax withholding executed by the issuer rather than a discretionary open-market sale
Negative
  • Reduction in direct ownership from the tax withholding leaves the reporting person with 176,990 shares
  • Initial filing omitted the withholding detail, requiring an amendment to correct records

Insights

TL;DR: Routine tax-withholding share disposition by an insider; limited investor impact.

The amendment clarifies that 8,424 shares were withheld to satisfy tax obligations at a price of $14.83, a non-market transfer executed by the issuer. This reduces the reporting person's direct ownership to 176,990 shares. For investors, this is an administrative event that typically has minimal signaling value about management's view of the company, since it is not a discretionary open-market sale.

TL;DR: Disclosure correction improves transparency; nature of transaction appears routine.

The Form 4/A corrects an omission in an earlier Form 4 by reporting issuer withholding of shares for tax purposes. Timely and accurate insider reporting is important for governance and market confidence. Because the transaction is withholding to satisfy tax liability, it does not indicate a deliberate liquidity decision by the insider beyond fulfilling tax obligations.

Una modifica interna di CorMedix segnala una cessione di azioni per ritenuta fiscale effettuata da Elizabeth Hurlburt, Chief Operating Officer e membro del consiglio. La comunicazione indica che 8.424 azioni ordinarie sono state trattenute dall'emittente a un prezzo effettivo di 14,83$ per coprire l'obbligo fiscale della soggetta alla segnalazione, riducendo la sua partecipazione diretta a 176.990 azioni. Il Modulo 4/A corregge una dichiarazione precedente per includere questa ritenuta. Si precisa che si tratta di una trattenuta automatica per tasse e non di una vendita sul mercato aperto, e che non sono state riportate operazioni su strumenti derivati.

Una enmienda interna de CorMedix informa de una disposición de acciones retenidas por impuestos realizada por Elizabeth Hurlburt, la directora de operaciones y miembro del consejo. El documento muestra que 8.424 acciones ordinarias fueron retenidas por el emisor a un precio efectivo de 14,83$ para satisfacer la obligación fiscal de la persona informante, reduciendo su propiedad beneficiaria directa a 176.990 acciones. El Formulario 4/A enmienda una presentación previa para revelar este importe retenido. Se aclara que se trata de una retención de acciones por impuestos de carácter mecánico, no de una venta en el mercado abierto, y no se informan transacciones con derivados.

코르메딕스 내부 수정 보고서에 따르면 최고운영책임자(COO) 겸 이사인 엘리자베스 헐버트가 세금 원천징수를 위해 주식을 처분한 것으로 보고되었습니다. 제출서류에는 보고자의 세금 부담을 충당하기 위해 발행사가 보통주 8,424주를 유효 가격 주당 14.83달러로 원천징수했으며, 이에 따라 그녀의 직접적 실질 소유는 176,990주로 감소했다고 기재되어 있습니다. Form 4/A는 이전 제출을 정정하여 이 원천징수분을 공개합니다. 이는 개방 시장에서의 매도가 아니라 세금을 위한 기계적 주식 원천징수이며, 파생상품 거래는 보고되지 않았습니다.

Un amendement interne de CorMedix signale une cession d'actions par retenue fiscale réalisée par Elizabeth Hurlburt, directrice des opérations et administratrice. Le dépôt indique que 8 424 actions ordinaires ont été retenues par l'émetteur à un prix effectif de 14,83 $ afin de couvrir la responsabilité fiscale de la personne déclarante, réduisant ainsi sa participation directe à 176 990 actions. Le formulaire 4/A corrige une déclaration antérieure pour divulguer ce montant retenu. Il s'agit d'une retenue d'actions à des fins fiscales de nature mécanique, et non d'une vente sur le marché ouvert, et aucune transaction sur dérivés n'est déclarée.

Eine interne Änderung bei CorMedix meldet eine aktienbezogene Steuerabzugsverfügung durch Elizabeth Hurlburt, die Chief Operating Officer und Direktorin des Unternehmens. Die Einreichung zeigt, dass 8.424 Stammaktien vom Emittenten zu einem effektiven Preis von 14,83$ einbehalten wurden, um die Steuerpflicht der meldepflichtigen Person zu erfüllen, wodurch ihr direktes wirtschaftliches Eigentum auf 176.990 Aktien reduziert wurde. Das Formular 4/A ändert eine frühere Meldung, um diesen einbehaltenen Betrag offenzulegen. Es handelt sich um eine mechanische Steuerabzugsmaßnahme und nicht um einen Verkauf am offenen Markt; Derivatgeschäfte wurden nicht gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hurlburt Elizabeth

(Last) (First) (Middle)
C/O CORMEDIX INC.
300 CONNELL DRIVE, SUITE 4200

(Street)
BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
09/03/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/29/2025 F 8,424 D $14.83 176,990(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On September 3, 2025, the Reporting Person filed a Form 4 that omitted the Issuer's withholding of common stock to satisfy the tax liability obligation of the Reporting Person. As reported in this amendment, the Issuer withheld 8,424 shares of common stock to satisfy the tax liability obligation of the Reporting Person.
/s/ Elizabeth Hurlburt 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elizabeth Hurlburt report on the Form 4/A for CRMD?

The filing discloses that the issuer withheld 8,424 shares of common stock to satisfy the reporting person's tax liability, leaving 176,990 shares beneficially owned.

Was the transaction an open-market sale or issuer withholding?

The transaction was an issuer withholding of shares to cover taxes, not an open-market sale executed by the reporting person.

At what price were the withheld shares recorded?

The withheld shares are listed with a price of $14.83 per share in the Form 4/A.

What is Elizabeth Hurlburt's role at CorMedix (CRMD)?

The filing identifies Elizabeth Hurlburt as a Director and the company's Chief Operating Officer.

Does the Form 4/A report any derivative transactions by the insider?

No. Table II lists no derivative securities; the filing reports only the non-derivative withholding of common stock.
Cormedix

NASDAQ:CRMD

CRMD Rankings

CRMD Latest News

CRMD Latest SEC Filings

CRMD Stock Data

951.77M
68.99M
7.3%
48.04%
14.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS